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Abstract. Polycyclic aromatic hydrocarbons (PAHs) are consid-
ered to be significant environmental carcinogens. Additionally, 
various planar ring systems are capable of intercalating with 
DNA, leading to a number of drugs that possess chemothera-
peutic activity. In this study, three new polyaromatic compounds 
with a side chain were synthesized, and spectroscopic as well 
as elemental analyses were performed. The addition of the 
long chains to either chrysene or pyrene caused a red-shift in 
the spectral emission when compared to the corresponding 
polycyclic aromatic hydrocarbons itself. Furthermore, the 
cytotoxicity of the three novel polyaromatic compounds was 
evaluated in vitro in a panel of cultured mammalian cell lines. 
The pyrenyl ether demonstrated better cytotoxicity compared 
to cisplatin against colon (HT-29) as well as cervical (HeLa) 
cancer cell lines. In conclusion, three new compounds were 
synthesized and investigated in this study. This novel method is 
likely to play a role in other areas of research.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are widely 
distributed in nature and are considered to be significant envi-
ronmental carcinogens. Although they are generally formed at 
high temperatures, PAHs should be considered as biologically 
inactive. The major sources of these hydrocarbons include, but 
are not limited to, power plants, gasoline, coal tar and diesel 
engines. PAHs are soluble in lipid, can be metabolized and 
are capable of interacting with cellular components, such as 
protein and nucleic acid. The metabolic activation of PAH 
is responsible for their carcinogenic properties. Since PAHs 
require metabolic activation, they are considered to be indirect 
acting carcinogens (1). On the other hand, DNA intercalators, 
an important class of antitumoral DNA binders, are character-
ized by the insertion of planar aromatic or heteroaromatic rings 
between DNA base pairs (2,3), as in the case of anthracyclines, 
acridines and ellipticines (4,5), which are thought to poison 
topoisomerases I and II (6). Various factors are involved in the 
stabilization of the drug-DNA complex, of which hydrogen 
bonding and π-stacking are the most important. Moreover, 
PAHs constitute an important class for the design of new 
chemotherapeutic DNA intercalators (7,8).
PAH-containing anticancer compounds were first reported 
to be present in either the anthracene (8-11) or the pyrene ring 
systems (1,12-14). DNA-binding molecules are considered to be 
an important class of drugs in anticancer therapy (15). Although 
it is well-established that DNA binding is not sufficient to confer 
cytotoxic activities, interaction with DNA is often considered 
a necessary criterion for maintaining a cytotoxic effect. The 
antitumoral anthracyclines daunorubicin and doxorubicin and 
the synthetic anthracene-9,10-dione mitoxantrone are potent 
agents in clinical use at present, with broad application in the 
treatment of several leukemias and lymphomas as well as in 
combination chemotherapy of solid tumors (16,17).
It is well-known that cancer is the leading cause of death in 
people under the age of 85 in the United States, and mortality 
from this disease appears to be on the increase (18). Therefore, 
it is imperative to develop new compounds and strategies to 
decrease the incidence and mortality of cancer. As a part of 
our ongoing research (7,19-29) to synthesize new PAH-bearing 
anticancer agents, we report the synthesis and in vitro cyto-
toxic evaluation of certain new PAH compounds (Fig. 1).
Materials and methods
Materials. The following materials were obtained for the study: 
PAH (chrysene and pyrene), bismuth nitrate pentahydrate, 
montmorillonite KSF clay, indium, ammonium chloride, 
isobutyl chloroformate, 1.0 M borane in tetrahydrofuran, 
reagent grade solvents (Aldrich Chemical Co., St. Louis, 
MO, USA), dimethylsulfoxide (DMSO; Sigma-Aldrich Corp., 
Polycyclic aromatic compounds as anticancer agents: 
Evaluation of synthesis and in vitro cytotoxicity
DEBASISH BANDYOPADHYAY1,  JOSE C. GRANADOS2,  JOHN D. SHORT2,3  and  BIMAL K. BANIK1
1Department of Chemistry, The University of Texas-Pan American, Edinburg, TX 78539; 2University of Texas Health 
Science Center at San Antonio-Regional Academic Health Center, Medical Research Division, Edinburg, TX 78541; 
3Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Received April 15, 2011;  Accepted June 20, 2011
DOI: 10.3892/ol.2011.436
Correspondence to: Dr John D. Short, University of Texas Health 
Science Center at San Antonio-Regional Academic Health Center, 
Medical Research Division, 1214 West Schunior Street, Edinburg, 
TX 78541, USA
E-mail: shortj@uthscsa.edu
Dr Bimal K. Banik, Department of Chemistry, The University of 
Texas-Pan American, 1201 West University Drive, Edinburg, Texas 
78539, USA
E-mail: banik@utpa.edu
Key words: polyaromatic, antitumor, cytotoxicity, liver cancer, 
emission spectrum
BANDYOPADHYAY et al:  POLYCYCLIC AROMATIC COMPOUNDS AS ANTICANCER AGENTS46
St. Louis, MO, USA), phosphate-buffered saline (PBS), 
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, 
Carlsbad, CA, USA), fetal bovine serum (FBS; Invitrogen), 
McCoy's media (Invitrogen) and doxorubicin (Fisher Scientific, 
Pittsburgh, PA, USA).
Synthesis of the compounds 1, 2 and 3. Melting points were 
determined in a Fisher Scientific electrochemical Mel-Temp* 
manual melting point apparatus (Model 1001) equipped with 
a 300˚C thermometer. Elemental analyses (C, H, N) were 
conducted using the Perkin-Elmer 2400 series II elemental 
analyzer. Their results were found to be in agreement (±0.2%) 
with the calculated values for C, H, N. FT-IR spectra were regis-
tered on a Bruker IFS 55 Equinox FT-IR spectrophotometer 
as KBr discs. 1H-NMR (300 MHz) and 13C-NMR (75.4 MHz) 
spectra were obtained at room temperature with JEOL Eclipse-
300 equipment using TMS as an internal standard and CDCl3 
as a solvent. Analytical grade chemicals (Sigma-Aldrich 
Corp.) were used throughout the study. Deionized water was 
used for the preparation of all aqueous solutions.
PAH nitration. Chrysene or pyrene (1 mmol) and montmo-
rillonite KSF clay (500 mg; Aldrich Chemical Co.) were added 
to a suspension of bismuth nitrate pentahydrate (1 mmol) in 
anhydrous dichloromethane (10 ml). The solvent was then 
evaporated under reduced pressure and the reaction mixture 
was irradiated in a kitchen microwave for 6 min (2x3 min). 
After every 2 min the reaction was monitored by TLC. After 
completion of the reaction, the reaction mixture was washed 
with dichloromethane (3x5 ml) and the solvent was evaporated 
by reduced pressure distillation. The pure product was isolated 
by crystallization from a dichloromethane/hexanes mixture in 
excellent yield (>90%).
Reduction of the nitrated PAH to the corresponding amine. 
The nitrated PAH (1 mmol) and indium (570 mg), 2.5 ml 
ethanol and 2.5 ml 20% aqueous ammonium chloride solution 
were refluxed vigorously for 24 h (monitored by TLC). After 
completion of the reaction, the mixture was filtered through 
a Büchner funnel and the filtrate was extracted with dichlo-
romethane (2x3 ml). The dichloromethane layer was washed 
with brine and water successively and dried over anhydrous 
sodium sulfate. The pure amine was isolated by crystallization 
from a dichloromethane/hexanes mixture in excellent yield 
(>80%).
Coupling of the polyaromatic amines with isobutyl chloro-
formate. The polyaromatic amine (1 mmol) was stirred with 
triethylamine (3 mmol) in anhydrous dichloromethane (5 ml) 
at a temperature of -5 to 0˚C, (1.8 mmol in 2 ml anhydrous 
dichloromethane) was then added dropwise. Following the 
addition of Isobutyl chloroformate, the mixture was agitated 
for 24 h (monitored by TLC). After completion of the reaction, 
the mixture was washed with a saturated solution of sodium 
bicarbonate, brine and water successively. The pure product 
was isolated after column chromatography over silica gel 
(>70% yield).
Reduction of 2 to 3. Compound 2 (1 mmol) was refluxed 
with 6 ml of 1.0 M borane/tetrahydrofuran solution for 36 h. 
Then, 5 ml of 4% hydrochloric acid solution was added and the 
mixture was again refluxed for another 24 h. After completion 
of the reaction, the pH of the solution was maintained at ~7.0 by 
10% aqueous sodium hydroxide solution and the mixture was 
extracted with ethyl acetate (3x3 ml). The organic layer was 
washed with brine and water successively. The pure product 
(compound 3) was isolated after column chromatography over 
silica gel (78% yield).
Isobutyl chrysen-6-ylcarbamate (compound 1). mp 181˚C; 
IR (KBr disc, cm-1): 3278, 3269, 1695, 1535, 1239, 1165, 972, 
829; 1H-NMR δ (CDCl3, ppm): 0.99 (m, 6H, methyl), 2.00 (m, 
1H, methine), 3.98 (m, 2H, methylene), 7.19 (broad s, NH), 
7.89-8.09 (m, 11H, Ar-H); 13C-NMR (CDCl3, ppm) δ: 19.56 
(2C), 28.40, 70.76, 111.98, 119.78, 122.43, 122.47, 126.54, 
126.87, 126.89, 126.94, 126.98, 127.07, 127.98, 128.65, 128.69, 
129.87, 129.98, 130.08, 131.86, 131.99, 156.51. Anal. Calcd. for 
C23H21NO2: C, 80.44; H, 6.16; N, 4.08. Experimental: C, 80.30; 
H, 6.10; N, 3.91.
Isobutyl pyren-4-ylcarbamate (compound 2). mp 146-148˚C; 
IR (KBr disc, cm-1): 3282, 3276, 1696, 1560, 1527, 1241, 1112, 
971, 865; 1H-NMR δ (CDCl3, ppm): 1.01 (m, 6H, methyl), 
2.03 (m, 1H, methine), 4.06 (d, 2H, J=6.49 Hz, methylene), 
7.21 (broad s, NH), 7.98-8.14 (m, 9H, Ar-H); 13C-NMR 
(CDCl3, ppm) δ: 19.23 (2C), 28.14, 71.89, 120.12, 124.87, 
124.97(2C), 125.23 (2C), 125.35, 125.42 (2C), 126.21, 126.66, 
127.39, 127.88, 130.70, 130.92, 131.49, 155.11. Anal. Calcd. for 
C21H19NO2: C, 79.47; H, 6.03; N, 4.41. Experimental: C, 79.31; 
H, 5.91; N, 4.22.
N-(isobutoxymethyl)pyren-4-amine (compound 3). mp 
76-78˚C; IR (KBr disc, cm-1): 2692, 2669, 2643, 2358, 1600, 
1514, 1282, 827; 1H-NMR δ (CDCl3, ppm): 0.94 (m, 6H, 
methyl), 2.08 (m, 1H, methine), 3.01 (m, 2H, methylene), 3.30 
(m, 2H, methylene), 4.71 (broad s, NH), 7.31-8.06 (m, 9H, 
Ar-H); 13C-NMR δ (CDCl3, ppm): 21.88, 28.17, 31.24, 108.27, 
116.53, 119.44, 122.45, 123.03, 123.24, 123.36, 123.87, 124.21, 
125.71, 125.84, 126.01, 126.36, 126.54, 126.76, 127.12, 127.93, 
143.59. Anal. Calcd. for C21H21NO: C, 83.13; H, 6.98; N, 4.62. 
Experimental: C, 82.89; H, 6.61; N, 4.51.
Spectral analyses of the compounds 1, 2 and 3. Compounds 1, 
2 and 3 were dissolved in DMSO at a concentration of 20 mM. 
For spectral analyses, compounds were then diluted to 50 µM 
Figure 1. Synthesis of the compounds 1, 2 and 3.
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in either DMSO or PBS. The absorbance of each compound, 
dissolved in either DMSO or PBS, was then analyzed between 
the wavelengths of 350-700 nM using a SpextraMaxM5 
plate reader (Molecular Devices, Sunnyvale, CA, USA). 
In addition, diluted compounds were excited with light at a 
wavelength of 350 nM, and the subsequent light emission was 
analyzed between the wavelengths of 350-700 nM using a 
SpextraMaxM5 plate reader.
Mammalian cell culture. HepG2, Hepa1-6, NIH3T3 and 
HeLa cells were cultured in DMEM (Invitrogen) containing 
10% FBS (Invitrogen), Caco-2 cells were cultured in DMEM 
containing 20% FBS and HT-29 cells were cultured in McCoy's 
media (Invitrogen) containing 10% FBS. The cell lines were 
purchased from American Type Culture Collection (ATCC; 
Manassas, VA, USA) and incubated at 37˚C with 5% CO2.
Mammalian cell viability assay. Cells were plated onto a 
96-well dish (5,000 cells/well) and incubated overnight at 
37˚C. The following day, cells were treated with increasing 
dosages (3-100 µM) of each compound, which had been 
dissolved in DMSO. The DMSO concentration of treatments 
was limited to 0.5%, and cells were treated with DMSO alone 
(0.5%) or 10 µM doxorubicin as negative and positive controls 
for cytotoxicity, respectively. After 48 h, cells were fixed 
and cell viability was analyzed using the Sulforhodamine B 
colorimetric assay as previously described (30). Absorbance 
of SRB was measured utilizing a SpextraMaxM5 plate reader 
and absorbance values were normalized to non-treated cells. 
The normalized cell viability with increasing drug doses 
was plotted on a four-parameter logistical curve, and the 
IC50 of each compound in each cell line was calculated using 
SigmaPlot software (Systat Software, Inc., Chicago, IL, USA). 
Each compound was synthesized in two independent reactions 
and used in cell viability assays to generate dose-response 
curves. The mean IC50 (in µM), with the corresponding stan-
dard deviation of the two independent synthesis reactions, was 
then calculated.
Subcellular localization. Cells (7,200 cells/well) were plated 
onto Nunc Lab-TekII 8-chamber slides (Fisher Scientific) and 
incubated overnight at 37˚C. The following day, cells were 
treated with compound (50 µM) for 4 h. After treatment, 
cells were fixed with PBS containing 4% formaldehyde for 
25 min at room temperature. Then, they were permeabilized 
using PBS containing 0.2% Triton-X-100 for 5 min at room 
temperature and mounted using VectaShield mounting medium 
containing DAPI (Fisher Scientific). The cells were visualized 
using a Zeiss AxioImager.Z1 epifluorescent microscope (Carl 
Zeiss Microimaging, LLC, Thornwood, NY, USA) with EGFP 
(Excitation 470/40; Emission 525/50) and DAPI filters, and 
images were acquired using AxioVision Rel. 4.6 software 
(Zeiss).
Results and Discussion
Spectral emission of the compounds 1, 2 and 3. Previous 
reports have identified that the peak emission wavelength of 
pyrene is less than 400 nM, with a shoulder for that emission 
peak at approximately 420 nM (31,32). Similarly, chrysene was 
previously shown to exhibit a peak emission wavelength of less 
than 400 nM, with a shoulder for its emission peak at approxi-
mately 425 nM (33). Therefore, we aimed to determine whether 
PAH derivatives 1-3 would have an impact on the absorption 
and spectral emission patterns of these molecules. Although 
no significant absorbance was detected for compounds in this 
study, i.e., compounds 1, 2 and 3, at wavelengths between 350 
and 650 nM, we detected a fluorescence emission spectrum for 
each of the PAH derivatives. The peak emission wavelength 
for both isobutyl pyren-4-ylcarbamate (compound 2) and 
N-(isobutoxymethyl)pyren-4-amine (compound 3) occurred 
between 460 and 470 nM (Figs. 2 and 3). However, isobutyl 
chrysen-6-ylcarbamate (compound 1) exhibited a much smaller 
emission spectra (Fig. 4), with shoulders for its peak at 420 
and 525 nM, when compared to compounds 2 and 3 (ig. 4 vs. 
Figs. 1 and 2). The limited fluorescence of this compound was 
possibly due to its crystallizing in aqueous solution, since this 
emission peak was larger, albeit at the same wavelength, when 
compound 3 was dissolved in an organic solvent, DMSO (data 
Figure 2. Emission spectrum of the compound 2 [compound (50 µM) was 
diluted in PBS and excited at a wavelength of 350 nM].
Figure 3. Emission spectrum of the compound 3 [compound (50 µM) was 
diluted in PBS and excited at a wavelength of 350 nM].
Figure 4. Emission spectrum of the compound 1 [compound (50 µM) was 
diluted in PBS and excited at a wavelength of 350 nM].
BANDYOPADHYAY et al:  POLYCYCLIC AROMATIC COMPOUNDS AS ANTICANCER AGENTS48
not shown). Nonetheless, these data indicate that the addition of 
the long chains to either chrysene or pyrene caused a red-shift 
in spectral emission when compared to the PAHs (chrysene or 
pyrene).
Decreasing viability of multiple mammalian cell lines. 
Previous reports from our group and from other authors have 
shown that certain derivatives of PAHs, including pyrene and 
chrysene derivatives, reduce the viability of transformed cell 
lines (1,20,34), and some of these PAH derivatives have been 
reported to reduce cell viability by induction of apoptosis 
(34,35). Therefore, we tested the effects of compounds 1, 2 and 3 
on the viability of a small panel of human and mouse cell lines, 
including liver cancer cell lines (HepG2 and Hepa1-6), colon 
cancer cell lines (HT-29 and Caco-2), a cervical cancer cell line 
(HeLa) and NIH3T3 cells. Colon cancer and the HepG2 liver 
cancer cell lines were less susceptible to the effects of the three 
compounds when compared to other cell types; Caco-2 cells 
proved to be particularly resistant to the effects of these three 
compounds (Table I).
However, each compound was capable of reducing the 
viability of Hepa1-6, HeLa and NIH3T3 cells with an estimated 
IC50 value of 16 µM or lower (Table I). Although compound 2 
was generally slightly more cytotoxic than compound 1, 
little difference in cytotoxicity was noted when comparing 
the pyrene (2) and chrysene (1) PAH-coupled compounds. 
Similarly, little difference in cytotoxicity was observed when 
comparing compounds 2 and 3, suggesting that reduction of 
the carbamate group had little effect on the pyrene-coupled 
PAHs.
Since each of the three compounds was capable of reducing 
cell viability, at least of certain cancer and non-cancer cell 
lines, we also aimed to determine whether this reduction in 
cell viability occurred through the induction of apoptosis. 
We examined whether compounds 1, 2 and 3 treatment led to 
increased caspase 3/7 activity or increased DNA fragmentation 
(as measured by a TUNEL assay). We did not detect an increase 
in either of these apoptotic features in either HepG2 or Hepa1-6 
cells in response to treatment with any of the three compounds 
analyzed (data not shown). Taken together, these data suggest 
that the ability of compounds 1, 2 and 3 to reduce cell viability 
occurs through an apoptosis-independent mechanism.
A wide variety of planar ring systems are capable of 
intercalating with DNA, giving rise to many drugs that 
possess chemotherapeutic activity. In this context, three new 
polyaromatic derivatives containing polar side chains were 
systematically synthesized and investigated. The primary 
mode of action of these intercalators is believed to be their 
reversible binding to nuclear DNA, which causes inhibition of 
the replication process and, thus, cell death. As is well-known, 
cytotoxicity is not only dependent on the ability to interact 
with DNA. Instead, the drug must be capable of interacting 
with DNA to form a stable ternary DNA-intercalator-enzyme 
complex with a relatively long half-life in such a way that the 
enzymatic process cannot progress (11). Therefore, the low 
level of cytotoxicity observed for compounds 1-3 may be 
ascribed to an inability to access nuclear DNA or a low binding 
association (including a low affinity or highly transient inter-
action) to DNA.
Polyaromatic compounds 1-3 accumulate outside the cell 
nucleus. To determine whether the three novel polyaromatic 
compounds (i.e., compounds 1-3) were capable of accessing 
the nuclear DNA of cells, we examined their auto-fluorescent 
properties. HepG2 cells were treated with each compound (50 
µM). Cells were then fixed, stained with DAPI and observed 
using an epifluorescent microscope. Each of the three 
compounds was capable of being detected using a filter for 
enhanced green fluorescent protein, in accordance with their 
spectral emission properties (Figs. 2-4). We did not detect 
any of the three polyaromatic compounds in cell nuclei under 
these conditions, although compounds 1 and 2 formed crys-
tals at these concentrations (data not shown). Interesetingly, 
compound 3 accumulated in a punctate pattern outside 
the cell nuclei (Fig. 5). This pattern is similar to a previous 
Table I. Estimated IC50 values (in µM) for the compounds 1, 2 and 3 in a small panel of mammalian cell lines.
Compounds HepG2 Hepa1-6 Caco-2 HT-29 HeLa NIH3T3
1    31.8±12.6b 9.1±9.1 >50   30.5±10.0 10.5±3.80 16.4±5.1
2 30.4±5.0 5.9±2.5 36.3±3.6 20.7±3.8 16.2±3.80   13.5±11.6
3 39.6±7.1 9.9±5.2 >50 14.0±5.7   9.8±1.03 12.5a
Cisplatin 7.0 4.0 10.8 16.8 11.7  8.5
aBased on single dose-response curve. bMinimum of curve is ≥35% cell viability.
Figure 5. Subcellular localization of compound 3. HepG2 cells were treated 
with 50 µM of compound 3 as described in Materials and methods. The 
compound accumulated in a punctate pattern (shown in green) outside of the 
nucleus (indicated by white arrows in the left panel and DAPI staining in the 
right panel).
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study (34) showing that a pyrene derivate accumulated in 
the cytosol of cells. These data suggest that the low level of 
cytotoxicity observed for these compounds is more likely due 
to their inability to access nuclear DNA in cells rather than 
a low binding affinity for DNA, although no studies have 
been performed to assess the DNA binding affinity of these 
compounds.
In conclusion, the present synthetic protocol allows for the 
preparation of three new polyaromatic compounds. Structure 
elucidation was carried out by various spectroscopic as well as 
elemental analyses. The addition of the long-chains to either 
chrysene or pyrene caused a red-shift in spectral emission 
when compared to the corresponding PAH itself. Furthermore, 
the cytotoxicity of the three novel polyaromatic compounds 
was evaluated in vitro in a panel of mammalian cell lines. 
Results showed that compound 2 exhibited better cytotox-
icity compared to cisplatin against the HeLa cancer cell line, 
whereas compound 3, the pyrenyl ether, demonstrated better 
cytotoxicity against colon (HT-29) as well as cervical (HeLa) 
cancer cell lines. In summary, three new and promising anti-
cancer PAH derivatives have been synthesized, and structural 
modification of these compounds is in progress. In addition, 
the method for synthesis of compounds 1-3 reported in this 
study may have applications in other areas of research.
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